icon-folder.gif   Conference Reports for NATAP  
 
  63rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 9-12 2012
Back grey_arrow_rt.gif
 
 
 
The NS5A Inhibitor GS-5885 Is Safe and Well Tolerated in More Than 1000 Patients Treated in Phase 2 Studies
 
 
  Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
 
Gregory Everson1, Eric Lawitz2, Alex Thompson3, Mark Sulkowski4, Yanni Zhu5, Diana Brainard5, Laura Mendelson5, John McHutchison5, Phil S. Pang5, Jenny C. Yang5, Patrick Marcellin6, Nezam Afdhal7 1University of Colorado Denver, Aurora, CO, United States; 2Alamo Medical Research, San Antonio, TX , United States; 3St. Vincent's Hospital, Melbourne, Australia; 4Johns Hopkins University School of Medicine, Baltimore, MD , United States; 5Gilead Sciences, Inc., Foster City, CA, United States; 6Université Paris-Diderot, Hopital Beaujon, Clichy, France; 7Beth Israel Deaconess Medical Center, Boston, MA , United States

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif